Findings

What do systematic reviews say?

5 questions · 5 findings · 4 reviews · Eyes and Vision

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 20%Low 1 · 20%Moderate 3 · 60%High 0 · 0%

Anti‐VEGF vs control

Serious systemic adverse events · CNV in people with pathologic myopia

It is very uncertain whether anti‐VEGF changes systemic serious adverse events compared with control (very low certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia 2016 · Cochrane Headline outcomes only
RR 4.5 [0.6, 33.99]
4 studies · 508 participants
Very low

Intervention not reported

All serious systemic adverse events · patients with neovascular age‐related macular degeneration

The intervention showed no clear difference in all serious systemic adverse events (low certainty).

1 finding from 1 review

Systemic safety of bevacizumab versus ranibizumab for neovascular age‐related macular degeneration 2014 · Cochrane Headline outcomes only
RR 1.08 [0.9, 1.31]
9 studies · 3665 participants
Low

Anti‐VEGF vs control

Serious systemic adverse events at one year · people with neovascular age‐related macular degeneration

Summary of findings: anti‐VEGF treatment showed no clear difference in serious systemic adverse events at 1 year compared with control (moderate certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
RR 0.17 [0.01, 4.24]
6 studies · 2667 participants
Moderate

Summary of findings: bevacizumab vs ranibizumab

Serious systemic adverse events at one year · people with neovascular age‐related macular degeneration

Summary of findings: bevacizumab showed no clear difference in serious systemic adverse events at 1 yearb compared with ranibizumab (moderate certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
RR 1.15 [0.99, 1.34]
6 studies · 3365 participants
Moderate

Intervention not reported

Adverse events ‐ serious systemic events at 1 year · people with age‐related macular degeneration

The intervention showed no clear difference in adverse events ‐ serious systemic events at 1 year (moderate certainty).

1 finding from 1 review

Aflibercept for neovascular age‐related macular degeneration 2016 · Cochrane Headline outcomes only
RR 0.99 [0.79, 1.25]
2 studies · 2419 participants
Moderate